Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis and symptomatic GERD
* Healing of NSAID-associated gastric ulcers
* Prevention of gastric ulcers in patients receiving concurrent NSAIDs
* Part of *Helicobacter pylori* eradication regimens
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. Maintenance therapy: 20-40 mg once daily.
* **Healing of NSAID-associated ulcers:** 40 mg orally once daily for up to 8 weeks.
* **Prevention of NSAID-associated ulcers:** 20 mg orally once daily.
* ***H. pylori* eradication:** 40 mg orally twice daily for 7-14 days (in combination with antibiotics).
Maximum daily dose: 40 mg intravenously, 80 mg orally (divided into 40 mg twice daily for short-term treatment of GERD).
## Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1-5 years (15-40 kg):** 20 mg orally once daily.
* **6-11 years (15-40 kg):** 20-40 mg orally once daily.
* **12-17 years:** 40 mg orally once daily.
* Dosing for intravenous administration in pediatric patients is not well-established and may depend on local protocols.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose is 40 mg orally once daily.
## Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Less Common: Rash, pruritus, insomnia, myalgia.
Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia, vitamin B12 deficiency, fundic gland polyps.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, certain antiretrovirals (e.g., atazanavir). Concomitant use may decrease absorption and efficacy.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole can inhibit CYP2C19, potentially increasing levels of drugs like clopidogrel (though clinical significance is debated).
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider monitoring serum magnesium levels, especially with prolonged use (e.g., >1 year) or in patients taking concomitant medications such as digoxin or diuretics.
* Assess for bone fracture risk with long-term therapy.
* Monitor for vitamin B12 deficiency with very long-term therapy.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal for optimal acid suppression.
* Intravenous pantoprazole is generally reserved for patients who cannot take oral medications.
* Long-term PPI use is associated with increased risks of fractures, *C. difficile* infection, and hypomagnesemia; use the lowest effective dose for the shortest duration necessary.
* Tapering PPIs may be considered when discontinuing to minimize rebound acid hypersecretion.
***
*This information is for educational purposes only and does not substitute for professional medical advice. Always verify current prescribing information with the official product labeling or a reliable drug information resource before making clinical decisions.*
